New Methods Of Treatment Parkinson's Disease

New Methods Of Treatment Parkinson's Disease.
Parkinson's plague has no cure, but three experiential treatments may help patients cope with unpleasant symptoms and related problems, according to immature research. The research findings will be presented at the annual meeting of the American Academy of Neurology in San Diego from March 16 to 23, 2013. "Progress is being made to increase our use of medications, promote new medications and to treat symptoms that either we haven't been able to treat effectively or we didn't gain were problems for patients," said Dr Robert Hauser, professor of neurology and principal of the University of South Florida Parkinson's Disease and Movement Disorders Center in Tampa. Parkinson's disease, a degenerative understanding disorder, affects more than 1 million Americans.

It destroys will cells in the brain that make dopamine, which helps control muscle movement. Patients trial shaking or tremors, slowness of movement, balance problems and a stiffness or rigidity in arms and legs. In one study, Hauser evaluated the hallucinogen droxidopa, which is not yet approved for use in the United States, to staff patients who experience a rapid fall in blood pressure when they stand up, which causes light-headedness and dizziness. About one-fifth of Parkinson's patients have this problem, which is due to a dud of the autonomic nervous procedure to release enough of the hormone norepinephrine when posture changes.

Hauser studied 225 people with this blood-pressure problem, assigning half to a placebo bring and half to take droxidopa for 10 weeks. The anaesthetize changes into norepinephrine in the body. Those on the medicine had a two-fold decline in dizziness and lightheadedness compared to the placebo group. They had fewer falls, too, although it was not a statistically significant decline.

In a number two study, Hauser assessed 420 patients who master a daily "wearing off" of the Parkinson's drug levodopa, during which their symptoms didn't respond to the drug. He compared those who took separate doses of a new drug called tozadenant, which is not yet approved, with those who took a placebo.

All still took the levodopa. At the inauguration of the study, the patients had an average of six hours of "off time" a date when symptoms reappeared. After 12 weeks, those on a 120-milligram or 180-milligram dose of tozadenant had about an hour less of "off time" each era than they had at the start of the study.